Q-omics provides the consensus-scored MIR3134 profile across patient tissues and cancer cell-line models. MIR3134 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, MIR3134 is differentially expressed in 3, with the highest sampling consensus in LIHC. Additionally, MIR3134 RNA expression shows 8,417 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUSC, LIHC, and GBM as cancer lineages where MIR3134 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3134 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3134 survival associations across molecular data types. MIR3134 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3134 RNA expression–survival associations across cancer types. High MIR3134 expression shows unfavorable associations in LUSC, TGCT and THCA, but favorable associations in READ, LAML and SKCM. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .028). Together, the overview and detailed table identify LUSC as the clearest survival context for MIR3134 RNA expression.
This table summarizes MIR3134 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3134. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3134 shows lower tumor expression in LUSC and ESCA and higher tumor expression in LIHC. The LIHC box plot shows higher MIR3134 RNA expression in tumor versus normal tissue (log2 FC = +0.261, t-test p = .001).
This table shows molecular features associated with MIR3134 in patient tissues and cancer cell lines. In patient samples, MIR3134 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
